Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02239224 · ClinicalTrials.gov registry record · Phase 1
Safety, Tolerability, Pharmacokinetics, and Biological Activity of ATYR1940 in Adult Participants With Muscular Dystrophy
A Phase 1 study, sponsored by aTyr Pharma.
- Completed
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
NCT02239224 is a Phase 1 study that has completed, run by aTyr Pharma. The registered enrollment target is 20 participants.
The verdict
NCT02239224, a Phase 1 study, has completed, sponsored by aTyr Pharma.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the safety and tolerability profile of ATYR1940 in the treatment of adult participants with molecularly defined genetic muscular dystrophies
Interventions
- BIOLOGICAL Placebo
- BIOLOGICAL ATYR1940
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2014-09-04 |
| Est. Completion | 2015-12-14 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02239224
The ClinicalTrials.gov registry entry for NCT02239224 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is aTyr Pharma, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02239224 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02239224 about?
NCT02239224 is a clinical study titled "Safety, Tolerability, Pharmacokinetics, and Biological Activity of ATYR1940 in Adult Participants With Muscular Dystrophy". The purpose of this study is to assess the safety and tolerability profile of ATYR1940 in the treatment of adult participants with molecularly defined genetic muscular dystrophies
What is the current status of trial NCT02239224?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2014-09-04. Estimated completion is 2015-12-14.
What interventions are being tested in trial NCT02239224?
The interventions under investigation include: Placebo (BIOLOGICAL), ATYR1940 (BIOLOGICAL).
Who is sponsoring clinical trial NCT02239224?
This trial is sponsored by aTyr Pharma, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.